Fostamatinib ITP denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for fostamatinib itp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Fostamatinib for ITP on Medical-Necessity Grounds

Aetna's medical-necessity denials for fostamatinib in immune thrombocytopenia (ITP) almost always come down to documentation gaps: the plan's reviewers could not confirm that the patient's clinical picture meets each requirement in Aetna's published coverage policy for this drug. Because fostamatinib (Tavalisse) is a later-line agent for a condition that has several treatment options, Aetna requires detailed proof that earlier approaches were tried, failed, or are contraindicated before it will authorize a newer targeted therapy.

## Why This Denial Is Appealable

FDA approved fostamatinib specifically for chronic ITP in adults who have had an insufficient response to a prior therapy, and robust professional society guidance from the American Society of Hematology (ASH) addresses second- and later-line management of ITP. A well-documented appeal can show that your clinical situation meets every element Aetna's policy requires. Insurance denials are frequently overturned at appeal when complete records are submitted.

## Federal Appeal Framework

• Internal appeal: Under ERISA §503 and ACA §2719, you have the right to a full-and-fair internal review. Submit within your plan's stated deadline (commonly 180 days from the denial notice).
• External review: If the internal appeal fails, you may request independent external review. Federal rules give you approximately four months from exhaustion of internal remedies. An independent organization — not Aetna — makes a binding decision.
• Expedited review: If your condition is urgent, you may request an expedited internal or external review, which compresses the timeline to days rather than weeks.

## Documentation to Gather

1. Diagnosis confirmation — pathology, CBC trends, and treating hematologist's records confirming chronic ITP and its duration. 2. Prior-treatment history — a dated, outcome-annotated list of every ITP therapy tried (corticosteroids, IVIG, thrombopoietin receptor agonists, rituximab, splenectomy if applicable), with start/stop dates and the reason each was discontinued or deemed inadequate. 3. Current clinical severity — recent platelet counts from the chart, any bleeding episodes, functional impact, and the prescriber's assessment of disease burden. 4. Prescriber medical-necessity letter — a letter from your hematologist that connects your specific chart findings to each criterion in Aetna's coverage policy and to the FDA-approved labeling indication.

## Criteria-Mapping Structure

Copy every requirement listed in Aetna's current coverage policy for fostamatinib (obtain the policy directly from Aetna's website or request it in writing). Next to each requirement, record the exact chart fact that satisfies it — the date, the result, the provider's words. Do the same for each element of the FDA-approved prescribing label's indication. This side-by-side table is the most persuasive format for a medical-necessity appeal and leaves no criterion unanswered.